Quick Answer
PTC THERAPEUTICS, INC. reported Cash and Equivalents of $984.65 million for fiscal year 2025.
PTC THERAPEUTICS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $984.65M | +26.3% |
| 2024 | $779.71M | +31.3% |
| 2023 | $594.00M | +112.3% |
| 2022 | $279.83M | +47.5% |
| 2021 | $189.72M | -9.1% |
| 2020 | $208.81M | -27.5% |
| 2019 | $288.03M | +69.9% |
| 2018 | $169.50M | +51.6% |
| 2017 | $111.79M | +91.7% |
| 2016 | $58.32M | +0.5% |
| 2015 | $58.02M | +16.6% |
| 2014 | $49.75M | +222.7% |
| 2013 | $15.41M | +465.4% |
| 2012 | $2.73M | -90.4% |
| 2011 | $28.43M | -0.8% |
| 2010 | $28.67M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $672.62M | +27.9% | -33.9% |
| June 30, 2025 | $1.02B | +55.4% | -31.3% |
| March 31, 2025 | $1.48B | +169.9% | +89.8% |
| December 31, 2024 | $779.71M | +31.3% | +48.2% |
| September 30, 2024 | $526.00M | +218.5% | -19.7% |
| June 30, 2024 | $654.78M | +214.2% | +19.4% |
| March 31, 2024 | $548.36M | +227.4% | -7.7% |
| December 31, 2023 | $594.00M | +112.3% | +259.7% |
- PTC THERAPEUTICS, INC. showed an increase of +26.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, PTC THERAPEUTICS, INC.’s cash and equivalents has grown by 3333.8% (from $28.67 million to $984.65 million).
- The most recent figure is from PTC THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: